| 1. |
Should all RhD-negative women receive antepartum prophylaxis? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 2-2
&NA;,
Preview
|
PDF (1195KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 2. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 3-3
&NA;,
Preview
|
PDF (1060KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 3. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 4-4
&NA;,
Preview
|
PDF (1179KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 4. |
Use of newer antihypertensives increasing, despite guidelines |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 5-5
&NA;,
Preview
|
PDF (1028KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 5. |
Dinitrochlorobenzene may decrease HIV viral burden |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 6-6
&NA;,
Preview
|
PDF (1091KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 6. |
Angiogenesis inhibitor/chemotherapy combo fights lung cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 7-8
Robert Carlson,
Preview
|
PDF (2194KB)
|
|
摘要:
Because malignant tumours use normal cellular mechanisms of vascularisation for growth function, oncologists have recently begun to explore angiogenesis as a valid therapeutic target. AGM-1470 [TNP-470; TAP Holdings] is an experimental first-generation anti-angiogenic agent that has been shown to potentiate standard anticancer therapiesin vivo. Although more potent angiogenesis inhibitors are now emerging, AGM-1470 is the furthest in development and the first to be testedin vivowith standard anticancer agents. The most recent animal trials combining AGM-1470 with standard antineoplastic drugs were described at the Chemotherapy Foundation Symposium XV [New York, US; November 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 7. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 8-8
&NA;,
Preview
|
PDF (1123KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 8. |
Raloxifene for prevention of bone loss and cardiovascular disease? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 9-9
&NA;,
Preview
|
PDF (1106KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 9. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 10-10
&NA;,
Preview
|
PDF (1207KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
| 10. |
Enoxaparin sodium has benefits as post-thrombolytic therapy in acute MI |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1117,
1997,
Page 11-12
Larry Prescott,
Preview
|
PDF (2284KB)
|
|
摘要:
Administration of the low molecular weight heparin (LMWH) enoxaparin sodium [‘Lovenox’; Rhône-Poulenc Rorer] in place of unfractionated heparin is proving to be of great value as post-thrombolytic therapy in patients with acute myocardial infarction (MI). This option is a well tolerated, efficacious, cost-effective, and more convenient alternative to unfractionated heparin, according to the results of study presented at the 70th Scientific Sessions of the American Heart Association [Orlando, US; November 1997]. In the study, enoxaparin sodium significantly reduced the risk of cardiac events compared to standard unfractionated heparin in patients with acute MI, reported Dr Charles Wilson, from Antrim Hospital, Northern Ireland.
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
首页
